S&P 500   4,548.14 (-0.05%)
DOW   35,402.02 (+0.19%)
QQQ   389.19 (+0.01%)
AAPL   189.79 (+0.00%)
MSFT   381.27 (+0.70%)
META   336.78 (+0.62%)
GOOGL   136.67 (+0.19%)
AMZN   146.64 (-0.74%)
TSLA   245.58 (+4.02%)
NVDA   476.14 (-1.30%)
NIO   7.23 (+0.56%)
BABA   76.45 (-1.39%)
AMD   121.45 (-0.98%)
T   16.10 (-0.68%)
F   10.36 (+0.19%)
MU   75.37 (-2.76%)
CGC   0.53 (-2.60%)
GE   118.79 (-0.98%)
DIS   92.86 (-2.43%)
AMC   6.69 (-1.62%)
PFE   29.68 (-1.53%)
PYPL   58.64 (+3.99%)
XOM   104.22 (+0.25%)
S&P 500   4,548.14 (-0.05%)
DOW   35,402.02 (+0.19%)
QQQ   389.19 (+0.01%)
AAPL   189.79 (+0.00%)
MSFT   381.27 (+0.70%)
META   336.78 (+0.62%)
GOOGL   136.67 (+0.19%)
AMZN   146.64 (-0.74%)
TSLA   245.58 (+4.02%)
NVDA   476.14 (-1.30%)
NIO   7.23 (+0.56%)
BABA   76.45 (-1.39%)
AMD   121.45 (-0.98%)
T   16.10 (-0.68%)
F   10.36 (+0.19%)
MU   75.37 (-2.76%)
CGC   0.53 (-2.60%)
GE   118.79 (-0.98%)
DIS   92.86 (-2.43%)
AMC   6.69 (-1.62%)
PFE   29.68 (-1.53%)
PYPL   58.64 (+3.99%)
XOM   104.22 (+0.25%)
S&P 500   4,548.14 (-0.05%)
DOW   35,402.02 (+0.19%)
QQQ   389.19 (+0.01%)
AAPL   189.79 (+0.00%)
MSFT   381.27 (+0.70%)
META   336.78 (+0.62%)
GOOGL   136.67 (+0.19%)
AMZN   146.64 (-0.74%)
TSLA   245.58 (+4.02%)
NVDA   476.14 (-1.30%)
NIO   7.23 (+0.56%)
BABA   76.45 (-1.39%)
AMD   121.45 (-0.98%)
T   16.10 (-0.68%)
F   10.36 (+0.19%)
MU   75.37 (-2.76%)
CGC   0.53 (-2.60%)
GE   118.79 (-0.98%)
DIS   92.86 (-2.43%)
AMC   6.69 (-1.62%)
PFE   29.68 (-1.53%)
PYPL   58.64 (+3.99%)
XOM   104.22 (+0.25%)
S&P 500   4,548.14 (-0.05%)
DOW   35,402.02 (+0.19%)
QQQ   389.19 (+0.01%)
AAPL   189.79 (+0.00%)
MSFT   381.27 (+0.70%)
META   336.78 (+0.62%)
GOOGL   136.67 (+0.19%)
AMZN   146.64 (-0.74%)
TSLA   245.58 (+4.02%)
NVDA   476.14 (-1.30%)
NIO   7.23 (+0.56%)
BABA   76.45 (-1.39%)
AMD   121.45 (-0.98%)
T   16.10 (-0.68%)
F   10.36 (+0.19%)
MU   75.37 (-2.76%)
CGC   0.53 (-2.60%)
GE   118.79 (-0.98%)
DIS   92.86 (-2.43%)
AMC   6.69 (-1.62%)
PFE   29.68 (-1.53%)
PYPL   58.64 (+3.99%)
XOM   104.22 (+0.25%)

Aprea Therapeutics Stock Price, News & Analysis (NASDAQ:APRE)

$3.75
+0.06 (+1.63%)
(As of 02:31 PM ET)
Compare
Today's Range
$3.75
$3.95
50-Day Range
$3.41
$5.33
52-Week Range
$2.78
$12.00
Volume
1,937 shs
Average Volume
22,826 shs
Market Capitalization
$14.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50

Aprea Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
268.0% Upside
$14.50 Price Target
Short Interest
Healthy
3.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.07) to ($1.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

531st out of 935 stocks

Pharmaceutical Preparations Industry

247th out of 435 stocks


APRE stock logo

About Aprea Therapeutics Stock (NASDAQ:APRE)

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

APRE Stock Price History

APRE Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Aprea Therapeutics GAAP EPS of -$0.86
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Aprea Therapeutics (APRE) Gets a Buy from Maxim Group
RLFTF Relief Therapeutics Holding AG
See More Headlines
Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APRE
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.50
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+268.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-112,660,000.00
Pretax Margin
-2,330.88%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.66 per share

Miscellaneous

Free Float
2,956,000
Market Cap
$14.74 million
Optionable
Not Optionable
Beta
0.77
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Oren Gilad Ph.D. (Age 54)
    Co-Founder, CEO, President and Director
    Comp: $520.84k
  • Mr. John P. Hamill CPA (Age 59)
    Senior VP, CFO, Principal Accounting Officer & Secretary
  • Dr. Dansu Li Ph.D.
    Head of Technology
  • Dr. Lars B. Abrahmsen Ph.D. (Age 66)
    Senior VP & Chief Scientific Officer
  • Dr. Michel Afargan Ph.D.
    Head of Pharmacology Development
  • Mr. Ze'ev Weiss B.Sc. (Age 61)
    C.P.A., Chief Business Advisor
  • Ms. Andrea Epstein
    Controller














APRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aprea Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APRE shares.
View APRE analyst ratings
or view top-rated stocks.

What is Aprea Therapeutics' stock price target for 2024?

3 brokers have issued twelve-month price targets for Aprea Therapeutics' shares. Their APRE share price targets range from $9.00 to $20.00. On average, they anticipate the company's share price to reach $14.50 in the next year. This suggests a possible upside of 267.1% from the stock's current price.
View analysts price targets for APRE
or view top-rated stocks among Wall Street analysts.

How have APRE shares performed in 2023?

Aprea Therapeutics' stock was trading at $6.62 at the beginning of 2023. Since then, APRE stock has decreased by 40.3% and is now trading at $3.95.
View the best growth stocks for 2023 here
.

When is Aprea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our APRE earnings forecast
.

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) posted its quarterly earnings data on Monday, November, 8th. The company reported ($9.00) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($9.00).

When did Aprea Therapeutics' stock split?

Aprea Therapeutics's stock reverse split before market open on Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).

When did Aprea Therapeutics IPO?

(APRE) raised $52 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

Who are Aprea Therapeutics' major shareholders?

Aprea Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Capital LLC (2.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Eyal C Attar, Gregory Alan Korbel and Lars B Abrahmsen.
View institutional ownership trends
.

How do I buy shares of Aprea Therapeutics?

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:APRE) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -